Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force (Q44595079)
Jump to navigation
Jump to search
scientific article published in July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force |
scientific article published in July 2013 |
Statements
1 reference
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force (English)
1 reference
Philip Scheltens
1 reference
Harald Hampel
1 reference
Reisa Sperling
1 reference
Cristina Sampaio
1 reference
Maria C Carrillo
1 reference
Bruno Vellas
1 reference
Paul Aisen
1 reference
Zaven Khachaturian
1 reference
Lon S Schneider
1 reference
Michael Weiner
1 reference
Rachelle Doody
1 reference
Ezio Giacobini
1 reference
Sandrine Andrieu
1 reference
Eric Siemers
1 reference
Jesse Cedarbaum
1 reference
Michael Grundman
1 reference
Karl Broich
1 reference
Jacques Touchon
1 reference
H Robert Brashear
1 reference
Bruno Dubois
1 reference
Gordon K Wilcock
1 reference
Suzanne Hendrix
1 reference
EU/US/CTAD Task Force Members
1 reference
1 July 2013
1 reference
1 reference
9
1 reference
4
1 reference
438-444
1 reference
Identifiers
1 reference
1 reference